Skip to main content
. 2006 Nov 28;56(6):927–938. doi: 10.1007/s00262-006-0237-4

Fig. 5.

Fig. 5

An anti-HER-2/neu specific monoclonal antibody is capable of controlling NT-2 tumor growth in FVB/N HER-2/neu transgenic mice. Mice were given tumors and injected with both the Listeria-based vaccines and either a control (a) or the 7.21.2 anti-HER-2/neu antibody (b) on days 7, 14, 21, 28, and 35. Groups are shown as an average tumor size at each time point. Both the PBS and Lm-LLO-NYESO-1, anti-HER-2/neu antibody groups are significantly better at day 42 than the PBS and Lm-LLO-NYESO-1 control antibody groups (P < 0.0001). Each of the Lm-LLO-HER-2/neu vaccine groups co-administered with the anti-HER-2/neu specific antibody is also significantly better at day 42 than the vaccine groups with the control antibody (P < 0.01)